All In Biotech

Drug Trial Radar · NCT05639894

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

A Phase I/IIa, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV Vaccine Candidate in Adult Participants 18 to 50 Years of Age in Phase I, and 60 Years and Older in Phase IIa

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 865 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

865

Actual

Start

Nov 17, 2022

Primary completion

May 2, 2025

Study completion May 2, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Brief Summary of Stage 1: The purpose of Stage 1 (Phase I/IIa) was to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 dose-levels of an Respiratory Syncytial Virus (RSV) vaccine candidate formulated with 2 different lipid nanoparticles (LNPs) in healthy adult participants aged between 18 to 50 years, and 60 years and older. The primary objectives of this stage were to assess the safety and immunogenicity profiles across the dose-level groups (low, medium, and high doses) with 2 LNPs. This stage evaluated the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population. Brief Summary of Stage 2: The study also incorporated a Stage 2 (Phase IIa, dose-ranging design) that included adults aged 60 years and older to assess the safety and immunogenicity of different doses of RSV vaccine encapsulated in one of the LNPs. In the Phase IIa dose-ranging stage, eligible participants were randomly assigned in a 1:1:1 ratio to receive a single IM administration of RSV vaccine candidate doses, or placebo. Multiple safety analyses were performed, minimally at D07 and D28.

Conditions

  • Respiratory Syncytial Virus Immunization

Interventions

  • RSV vaccine candidateBiological

    Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection

  • PlaceboOther

    Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)Time frame: Up to 30 minutes post-primary vaccination on Day 1
  2. Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Solicited Injection Site Reactions and Systemic ReactionsTime frame: From Day 1 (first dose of primary vaccination) up to Day 8 (7 days post-primary vaccination on Day 1)
  3. Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Unsolicited Adverse EventsTime frame: From Day 1 (first dose of primary vaccination) up to Day 29 (28 days post-primary vaccination on Day 1)
  4. Stage 1 (Sentinel and Main Cohort): Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: From Day 1 (first dose of primary vaccination) up to Day 29 (28 days post-primary vaccination on Day 1)
  5. Stage 2: Number of Participants With Medically Attended Adverse EventsTime frame: From Day 1 (first dose of primary vaccination) to Day 180
  6. Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Time frame: From Day 1 (first dose of primary vaccination) to Day 365 (Stage 1 Sentinel and Main Cohorts); From Day 1 (first dose of primary vaccination) to Day 180 (Stage 2)
  7. Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Shifts From Baseline to Out-of-Range Biological Test ResultsTime frame: From baseline (Day -14 to Day -1) up to Day 8 (7 days post-primary vaccination on Day 1)
  8. Stage 1 (Sentinel and Main Cohort): Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Respiratory Syncytial Virus ATime frame: Day 1 (pre-primary vaccination) and Day 29 (28 days post-primary vaccination on Day 1)
  9. Stage 2: Geometric Mean Titers of Neutralizing Antibodies Against Respiratory Syncytial Virus A and Respiratory Syncytial Virus BTime frame: Day 1 (pre-primary vaccination) and Day 29 (28 days post-primary vaccination on Day 1)

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Optimal Research Alabama Site Number : 8400032

    Huntsville, Alabama

  • Aventiv Research Mesa Site Number : 8400020

    Mesa, Arizona

  • CVS Health - Peoria Site Number : 8400042

    Peoria, Arizona

  • CVS Health - Phoenix Site Number : 8400041

    Phoenix, Arizona

  • Velocity Clinical Research - San Diego - ERN - PPDS Site Number : 8400010

    La Mesa, California

  • Peninsula Research Associates Site Number : 8400013

    Rolling Hills Estates, California

  • CVS Health - Thousand Oaks Site Number : 8400043

    Thousand Oaks, California

  • Cenexel Research Centers of America Site Number : 8400024

    Hollywood, Florida

  • Suncoast Research Associates, LLC Site Number : 8400003

    Miami, Florida

  • Centricity Research - Georgia Site Number : 8400009

    Rincon, Georgia

  • AES Peoria Site Number : 8400030

    Peoria, Illinois

  • DM Clinical Research - Chicago Site Number : 8400027

    River Forest, Illinois

  • Be Well Clinical Studies Site Number : 8400036

    Lincoln, Nebraska

  • Velocity Clinical Research Site Number : 8400019

    Cincinnati, Ohio

  • Velocity Clinical Research Site Number : 8400017

    Cleveland, Ohio

  • Aventiv Research Columbus Site Number : 8400007

    Columbus, Ohio

  • Lynn Institute of Norman Site Number : 8400023

    Norman, Oklahoma

  • Velocity Clinical Research, Medford Site Number : 8400014

    Medford, Oregon

  • Velocity Clinical Research - Providence Site Number : 8400006

    East Greenwich, Rhode Island

  • Coastal Carolina Research Center Site Number : 8400015

    North Charleston, South Carolina

  • DM Clinical Research - CyFair Site Number : 8400025

    Houston, Texas

  • Be Well Clinical Studies -Round Rock Site Number : 8400038

    Round Rock, Texas

  • IMA Clinical Research-San Antonio Site Number : 8400039

    San Antonio, Texas

  • Martin Diagnostic Clinic Site Number : 8400026

    Tomball, Texas

  • Velocity Clinical Research Site Number : 8400018

    West Jordan, Utah

  • Investigational Site Number : 0360001

    Southport, Australia

  • Investigational Site Number : 0360003

    Botany, New South Wales, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, Australia

  • Investigational Site Number : 6300004

    Carolina, Puerto Rico

  • Investigational Site Number : 6300003

    Guayama, Puerto Rico

  • Investigational Site Number : 6300005

    Guaynabo, Puerto Rico

  • Investigational Site Number : 6300001

    San Juan, Puerto Rico

  • Investigational Site Number : 6300002

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.